In This Article:
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly.
Top 5 Upgrades:
-
DA Davidson upgraded Microsoft (MSFT) to Buy from Neutral with a price target of $450, up from $425, as the firm believes the company has moved to a more rational capex strategy and is "the best positioned Mag6 for a slowing consumer."
-
BofA upgraded Intel (INTC) to Neutral from Underperform with a price target of $25, up from $19. The firm "really" likes the new CEO appointment, but notes that the share upside potential is balanced against risks from a lack of artificial intelligence roadmap and increasing competition in a tough macro environment.
-
Barclays upgraded Molson Coors (TAP) to Equal Weight from Underweight with a price target of $62, up from $56. The firm sees "reason to be incrementally constructive" on Molson shares.
-
Stephens upgraded Alkami (ALKT) to Overweight from Equal Weight with a $40 price target, citing the firm's belief that the 34% year-to-date decline in the shares has created "a favorable entry point."
-
Mizuho upgraded Invitation Homes (INVH) to Outperform from Neutral with a price target of $36, up from $33. The firm sees the single-family rental sector as a net winner amid the macro uncertainty given their more "defensive tenancy and stickier cash flows."
Top 5 Downgrades:
-
BofA downgraded UiPath (PATH) to Underperform from Neutral with a price target of $10, down from $18, following the company's "disappointing" FY26 outlook. Macro pressure in the Federal vertical was cited, though commentary suggests that pressure is more broad-based and "unlikely to abate soon," says the firm, which sees few catalysts for the shares, even at current level.
-
Morgan Stanley double downgraded Moelis (MC) to Underweight from Overweight with a price target of $70, down from $100. Given the "risk-off environment," Morgan Stanley would have expected to see the shares underperform the group, but it is down 19%, de-rating less than others.
-
Needham downgraded Dentsply Sirona (XRAY) to Hold from Buy without a price target. With a debate around whether the dental market's long-term growth profile has shifted lower and recent indicators pointing to weakening U.S. consumer sentiment, Needham does not expect dental market growth to improve in the near-term.
-
BofA downgraded Vivid Seats (SEAT) to Underperform from Buy with a price target of $2.60, down from $6.25. The firm noticed a "tonal shift" in management's 2025 outlook for live events as the industry has now trended negative for the last six weeks from double-digit growth at the start of 2025.
-
JPMorgan downgraded Cipher Mining (CIFR) to Neutral from Overweight without a price target. The firm now sees less upside potential relative to peers for Cipher Mining shares.